S&P 500
$5,958.38
+0.7%
+$41.45
DJI
$42,654.74
+0.8%
+$331.99
NASDAQ
$19,211.10
+0.5%
+$98.78
Bitcoin
$103,195.00
-0.8%
-$806.96
AAPL
$211.31
-0.1%
-$0.14
AMZN
$205.54
+0.2%
+$0.37
GOOG
$167.32
+1.2%
+$1.92
META
$640.11
-0.6%
-$3.77
MSFT
$453.88
+0.2%
+$0.75
NVDA
$135.20
+0.3%
+$0.38
TSLA
$349.44
+1.9%
+$6.62
Avalo Therapeutics (NASDAQ: CERC)
$3.86
(0.0%)
$0.00
Price as of May 16, 2025, 3:55 p.m. ET
Avalo Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Avalo Therapeutics Company Info
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.